Kornitzer Capital Management Inc. KS Grows Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Kornitzer Capital Management Inc. KS increased its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 10.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 38,517 shares of the medical research company’s stock after buying an additional 3,564 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in Bio-Rad Laboratories were worth $12,887,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in BIO. Vanguard Group Inc. boosted its stake in shares of Bio-Rad Laboratories by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 2,421,334 shares of the medical research company’s stock worth $837,467,000 after buying an additional 31,445 shares during the last quarter. Van ECK Associates Corp boosted its position in Bio-Rad Laboratories by 97.8% in the third quarter. Van ECK Associates Corp now owns 1,303,752 shares of the medical research company’s stock worth $436,861,000 after purchasing an additional 644,530 shares during the last quarter. Select Equity Group L.P. boosted its position in Bio-Rad Laboratories by 26.2% in the second quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock worth $177,391,000 after purchasing an additional 134,856 shares during the last quarter. First Eagle Investment Management LLC increased its position in shares of Bio-Rad Laboratories by 32,296.9% during the 2nd quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock valued at $173,773,000 after purchasing an additional 634,311 shares during the last quarter. Finally, Earnest Partners LLC lifted its stake in shares of Bio-Rad Laboratories by 17.8% in the 2nd quarter. Earnest Partners LLC now owns 606,788 shares of the medical research company’s stock worth $165,720,000 after purchasing an additional 91,882 shares during the period. Institutional investors own 65.24% of the company’s stock.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares of the company’s stock, valued at approximately $48,582.03. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the transaction, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at $2,494,016.46. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP James Barry sold 623 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now owns 147 shares in the company, valued at $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 17.50% of the company’s stock.

Bio-Rad Laboratories Price Performance

Shares of BIO traded up $1.18 during trading hours on Thursday, reaching $374.11. 7,081 shares of the stock traded hands, compared to its average volume of 247,249. The company has a market cap of $10.43 billion, a P/E ratio of -13.64 and a beta of 0.93. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The company’s 50-day moving average price is $337.07 and its two-hundred day moving average price is $310.43. Bio-Rad Laboratories, Inc. has a 52-week low of $262.12 and a 52-week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The business had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. During the same period in the previous year, the business earned $2.33 earnings per share. The business’s revenue was up 2.8% on a year-over-year basis. On average, analysts anticipate that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on BIO shares. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price for the company. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Citigroup raised their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Royal Bank of Canada boosted their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $391.80.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.